A Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety and Pharmacokinetic Profile of Staccato Granisetron (AZ-010) in Healthy Volunteers
Latest Information Update: 02 Nov 2020
Price :
$35 *
At a glance
- Drugs Granisetron (Primary)
- Indications Nausea and vomiting
- Focus Adverse reactions
- Sponsors Alexza Pharmaceuticals
- 05 Oct 2020 Status changed from recruiting to completed.
- 02 Apr 2020 New trial record